Working... Menu
Trial record 2 of 3 for:    APG-1252

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03080311
Recruitment Status : Recruiting
First Posted : March 15, 2017
Last Update Posted : March 15, 2019
Information provided by (Responsible Party):
Ascentage Pharma Group Inc.

Brief Summary:

APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w. The preclinical studies have shown that APG-1252 alone achieves complete and persistent tumor regression in multiple tumor xenograft models with a twice weekly or weekly dose-schedule, including SCLC, colon, breast and ALL cancer xenografts; achieves strong synergy with the chemotherapeutic agents, indicating that APG-1252 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-1252 is intended for the treatment of patients with SCLC or other solid tumors.

This is a multi-center, open-label, dose escalation Phase I study to determine the MTD and DLTs of intravenously administered APG-1252. After dose escalation to 240mg twice weekly, 2 dose cohorts two different dosing schedules including weekly and twice weekly will be assessed to evaluate for safety, tolerability, PK and preliminary anti-tumor efficacy. Treatment with APG-1252 will be administered to 30-60 patients at approximately 2 investigational sites in US.

Condition or disease Intervention/treatment Phase
Small Cell Lung Cancer and Other Solid Tumors Drug: APG-1252 Phase 1

Detailed Description:

In dose cohort 1, patients will be treated in cycles, which are defined by APG-1252 intravenous administration on Days 1, 4, 8, 11, 15, 18 and 22, over a 28-day cycle the start dose is 10mg.

After dose escalation to 240mg twice weekly in dose cohort 1, dose cohort 2 will be performed with dose cohort 1 parallelly, patients will be treated in the same 28-day-cycles, APG-1252 intravenous administration on Days 1, 8, 15, and 22, the start dose is 240mg.

In both dose cohorts' patients could continue to receive cycles of APG-1252 until disease progress or unacceptable toxicity.

Study drug will be administered by intravenous infusion for 30 minutes at the investigational site by site staff.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description: Open label
Primary Purpose: Treatment
Official Title: A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients With Small Cell Lung Cancer (SCLC) or Other Solid Tumors
Actual Study Start Date : February 12, 2017
Estimated Primary Completion Date : June 12, 2019
Estimated Study Completion Date : September 12, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: APG-1252
An accelerated dose escalation scheme will be utilized initially with one patient enrolled per cohort. If at 10 mg or 20 mg dose level, any occurrence in cycle 1 of one ≥ Grade 2 adverse event related or possibly related to APG-1252 (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) is the trigger for converting to a standard 3+3 design at that dose level.
Drug: APG-1252

Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.


Other Name: APG-1252 for injection

Primary Outcome Measures :
  1. Dose limit toxicity (DLT) determination [ Time Frame: 18 - 24 months ]
    Number of participants with APG-1252 treatment-related adverse events as assessed by CTCAE v4.0

  2. Maximum tolerated dose (MTD) determination [ Time Frame: 18 - 24 months ]
    If ≥ 2/6 patients develop a DLT at any dose level, then this dose will be declared as the MTD

Secondary Outcome Measures :
  1. Pharmacokinetic evaluation [ Time Frame: 18 - 24 months ]
    Peak plasma concentration (Cmax) will be assessed on all participants with APG-1252 treatments

  2. Pharmacokinetic evaluation [ Time Frame: 18 - 24 months ]
    Area under the plasma concentration versus time curve (AUC) will be assessed on all participants with APG-1252 treatments

  3. Pharmacodynamic evaluation [ Time Frame: 18-24 months ]
    Platelet counts will be measured on the participants with APG-1252 treatments

  4. Pharmacodynamic evaluation [ Time Frame: 18-24 months ]
    Bcl-2 protein in PBMCs will be measured on the participants with APG-1252 treatments

  5. Pharmacodynamic evaluation [ Time Frame: 18-24 months ]
    Activation of apoptosis will be measured on the participants with APG-1252 treatments

  6. Preliminary efficacy assessment [ Time Frame: 18-24 months ]
    Patients will be evaluated for response every 2 cycles (i.e., 8 weeks), according to the new response evaluation criteria in solid tumors: revised RECIST Guideline, Version 1.1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically or cytologically confirmed small cell lung cancer (SCLC) or other solid tumors;
  2. Male or non-pregnant, non-lactating female patients age ≥18 years;
  3. Locally advanced or metastatic disease for which no standard therapy is judged appropriate by the investigator;
  4. Eastern Cooperative Oncology Group (ECOG) Performance Status < 2;
  5. Adequate hematologic function as indicated by:

    1. Platelet count ≥ 100,000/mm3
    2. Hemoglobin ≥ 9.0g/dL Platelet count ≥ 100,000/mm3
    3. Absolute neutrophil count (ANC) ≥1000/µL
  6. Adequate renal and liver function as indicated by:

    1. Serum creatinine ≤ 1.5 x upper limit of normal (ULN); if serum creatinine is >1.5 X ULN, creatinine clearance must be ≥ 50 mL/min (see Section 22.3).
    2. Total bilirubin ≤1.5 x ULN; If Gilbert's Syndrome may have Bilirubin> 1.5 x ULN
    3. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤3 x ULN of institution's normal range; for patients with known liver metastases, AST and ALT may be ≤ 5 x ULN.
    4. Coagulation: aPTT and PT<1.2 x the upper limit of normal
  7. Brain metastases with clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function & no evidence of CNS disease progression as determined by CT or MRI within 21 days prior to the first dose of study drug.
  8. Willingness to use contraception by a method that is deemed effective by the investigator by both males and female patients of child bearing potential (postmenopausal women must have been amenorrheal for at least 12 months to be considered of non-childbearing potential) and their partners throughout the treatment period and for at least three months following the last dose of study drug;
  9. Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures);
  10. Willingness and ability to comply with study procedures and follow-up examination.

Exclusion Criteria:

  1. Receiving concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, with the exception of hormones for hypothyroidism or estrogen replacement therapy (ERT), anti estrogen analogs, agonists required to suppress serum testosterone levels); or any investigational therapy, or has had tumor embolization or tumor lysis syndrome (TLS) within 14 days prior to the first dose of study drug.
  2. Steroid therapy for anti-neoplastic intent within 7 days prior to the first dose of study drug.
  3. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to < Grade 2;
  4. Known bleeding diathesis/disorder;
  5. Recent history of non-chemotherapy induced thrombocytopenia associated bleeding within 1 year prior to first dose of study drug.
  6. Have active immune thrombocytopenic purpura (ITP), active autoimmune hemolytic anemia (AIHA), or a history of being refractory to platelet transfusions (within 1 year prior to the first dose of study drug).
  7. Serious gastrointestinal bleeding within 3 months;
  8. Use of therapeutic doses of anti-coagulants is excluded, along with anti-platelet agents; low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter are permitted.
  9. Received a biologic (G-CSF, GM-CSF or erythropoietin) within 28 days prior to the first dose of study drug.
  10. Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry;
  11. Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry.
  12. Neurologic instability per clinical evaluation due to tumor involvement of the central nervous system (CNS). Patients with CNS tumors that have been treated, are asymptomatic and who have discontinued steroids (for the treatment of CNS tumors) for >28 days may be enrolled;
  13. Active symptomatic fungal, bacterial and/or viral infection including, but not limited to, active human immunodeficiency virus (HIV) or viral hepatitis (B or C);
  14. Diagnosis of fever and neutropenia within 1 week prior to study drug administration.
  15. Uncontrolled concurrent illness including, but not limited to: serious uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
  16. Prior treatment with Bcl-2/Bcl-xL inhibitors.
  17. Any other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.
  18. Known clinically active hepatitis B or hepatitis C infection. Testing for hepatitis B and C is not required for study enrollment.
  19. Known HIV infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03080311

Layout table for location contacts
Contact: Isabel Jimenez, RN, MSN 210-593-5265

Layout table for location information
United States, Michigan
START Midwest Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Kathy Estkowski, BS, CCRP    616-954-5554   
Contact: Timothy J Cole, RN, BSN, OCN    616-954-5554   
Principal Investigator: Nehal Lakhani, M.D., Ph.D.         
United States, Texas
The START Center for Cancer Care Recruiting
San Antonio, Texas, United States, 78229
Contact: Isabel Jimenez, RN, MSN    210-593-5265   
Principal Investigator: Drew Resco, M.D.         
Sponsors and Collaborators
Ascentage Pharma Group Inc.
Layout table for investigator information
Study Director: Yifan Zhai, M.D., Ph.D. Ascentage Pharma Group Inc.

Layout table for additonal information
Responsible Party: Ascentage Pharma Group Inc. Identifier: NCT03080311     History of Changes
Other Study ID Numbers: APG-1252-US-001
First Posted: March 15, 2017    Key Record Dates
Last Update Posted: March 15, 2019
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ascentage Pharma Group Inc.:
Bcl-2/Bcl-xL dual inhibitor

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms